Abivax SA Sponsored ADR (ABVX) Stock Forecast & Price Target

Compare

224 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABVX Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Abivax

SA Sponsored ADR

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABVX Stock 12 Month Forecast

Average Price Target

$106.17

▲(23.51% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Abivax SA Sponsored ADR in the last 3 months. The average price target is $106.17 with a high forecast of $116.00 and a low forecast of $95.00. The average price target represents a 23.51% change from the last price of $85.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","117":"$117","32.25":"$32.3","60.5":"$60.5","88.75":"$88.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$116.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,32.25,60.5,88.75,117],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,84.60615384615384,87.2223076923077,89.83846153846153,92.45461538461538,95.07076923076923,97.68692307692308,100.30307692307693,102.91923076923077,105.53538461538461,108.15153846153846,110.7676923076923,113.38384615384615,{"y":116,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,83.85,85.71,87.57,89.42999999999999,91.28999999999999,93.15,95.00999999999999,96.87,98.73,100.59,102.45,104.31,{"y":106.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,81.99,82.99076923076923,83.99153846153845,84.99230769230769,85.99307692307691,86.99384615384615,87.99461538461539,88.99538461538461,89.99615384615385,90.99692307692308,91.9976923076923,92.99846153846154,93.99923076923076,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.56,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$116.00

Average Price Target$106.17

Lowest Price Target$95.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Judah Frommer

Morgan Stanley

$71→$101

Buy

17.50%

Upside

Reiterated

09/12/25

Abivax price target raised to $101 from $71 at Morgan StanleyAbivax price target raised to $101 from $71 at Morgan Stanley

Julian Harrison

BTIG

$43→$112

Buy

30.29%

Upside

Reiterated

09/08/25

Promising Outlook for Abivax SA: Buy Rating Supported by Strong Clinical Results and Financial PositionWe continue to expect additional detailed ABTECT induction data at an upcoming medical conference (UEGW would be our best guess; abstracts are scheduled to be published on September 13). Abivax reiterated guidance for topline ABTECT Phase 3 maintenance results in 2Q26 following 8wk induction data in UC that was a sweeping success, in our view, with a pooled pbo-corrected rate of clinical remission that was well into our blue sky scenario (16.4% vs. our base case of 8.0% to 12.0%) and high confidence of progressively improving efficacy in maintenance. Obefazimod's safety profile continues to look "Entyvio-tier" which together with oral administration and a novel MOA should further support broad commercial uptake.

Sam Slutsky

LifeSci Capital

$101→$116

Buy

34.95%

Upside

Reiterated

09/01/25

LifeSci Capital Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX)

Allison Bratzel

Piper Sandler

$70→$112

Buy

30.29%

Upside

Reiterated

07/29/25

Abivax SA Sponsored ADR (ABVX) Receives a Buy from Piper Sandler

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

07/28/25

Jason Butler

Citizens JMP

$33→$95

Buy

10.52%

Upside

Reiterated

07/23/25

Abivax price target raised to $95 from $33 at Citizens JMPAbivax price target raised to $95 from $33 at Citizens JMP

Yatin Suneja

Guggenheim

$50→$101

Buy

17.50%

Upside

Reiterated

07/23/25

Abivax price target raised to $101 from $50 at GuggenheimAbivax price target raised to $101 from $50 at Guggenheim

Christopher Raymond

Raymond James

$42

Buy

-51.14%

Downside

Reiterated

02/10/25

Piper Sandler Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Judah Frommer

Morgan Stanley

$71→$101

Buy

17.50%

Upside

Reiterated

09/12/25

Abivax price target raised to $101 from $71 at Morgan StanleyAbivax price target raised to $101 from $71 at Morgan Stanley

Julian Harrison

BTIG

$43→$112

Buy

30.29%

Upside

Reiterated

09/08/25

Sam Slutsky

LifeSci Capital

$101→$116

Buy

34.95%

Upside

Reiterated

09/01/25

LifeSci Capital Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX)

Allison Bratzel

Piper Sandler

$70→$112

Buy

30.29%

Upside

Reiterated

07/29/25

Abivax SA Sponsored ADR (ABVX) Receives a Buy from Piper Sandler

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

07/28/25

Jason Butler

Citizens JMP

$33→$95

Buy

10.52%

Upside

Reiterated

07/23/25

Abivax price target raised to $95 from $33 at Citizens JMPAbivax price target raised to $95 from $33 at Citizens JMP

Yatin Suneja

Guggenheim

$50→$101

Buy

17.50%

Upside

Reiterated

07/23/25

Abivax price target raised to $101 from $50 at GuggenheimAbivax price target raised to $101 from $50 at Guggenheim

Christopher Raymond

Raymond James

$42

Buy

-51.14%

Downside

Reiterated

02/10/25

Piper Sandler Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abivax SA Sponsored ADR

1 Month

xxx

Success Rate

6/13 ratings generated profit

Average Return

+58.77%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 46.15% of your transactions generating a profit, with an average return of +58.77% per trade.

3 Months

xxx

Success Rate

7/13 ratings generated profit

Average Return

+180.23%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +180.23% per trade.

1 Year

Sam SlutskyLifeSci Capital

Success Rate

9/13 ratings generated profit

Average Return

+409.16%

reiterated a buy rating 12 days ago

Copying Sam Slutsky's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +409.16% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+696.28%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +696.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABVX Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABVX has received 13 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ABVX average Analyst price target in the past 3 months is 106.17.

Each month's total comprises the sum of three months' worth of ratings.

ABVX Financial Forecast

ABVX Earnings Forecast

Next quarter’s earnings estimate for ABVX is -$0.73 with a range of -$0.76 to -$0.70. The previous quarter’s EPS was -$0.89. ABVX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year ABVX has Outperformed its overall industry.

No data currently available

ABVX Sales Forecast

Next quarter’s sales forecast for ABVX is $1.47M with a range of $1.32M to $1.63M. The previous quarter’s sales results were $0.00. ABVX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.14% of the time in the same period. In the last calendar year ABVX has Preformed in-line its overall industry.

ABVX Stock Forecast FAQ

What is ABVX’s average 12-month price target, according to analysts?

Based on analyst ratings, Abivax SA Sponsored ADR’s 12-month average price target is 106.17.

What is ABVX’s upside potential, based on the analysts’ average price target?

Abivax SA Sponsored ADR has 23.51% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABVX a Buy, Sell or Hold?

Abivax SA Sponsored ADR has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Abivax SA Sponsored ADR’s price target?

The average price target for Abivax SA Sponsored ADR is 106.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $116.00 ,the lowest forecast is $95.00. The average price target represents 23.51% Increase from the current price of $85.96.

What do analysts say about Abivax SA Sponsored ADR?

Abivax SA Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of ABVX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Abivax SA Sponsored ADR (ABVX) Stock Forecast & Price Target

ABVX Analyst Ratings

ABVX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abivax SA Sponsored ADR

ABVX Analyst Recommendation Trends

ABVX Financial Forecast

ABVX Earnings Forecast

ABVX Sales Forecast

ABVX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts